Sign In
Buy SYBX
$0.600
+0 (+0%)
At Close: Jun 03, 2026
Synlogic Reports Third Quarter 2024 Financial Results
04:35pm, Tuesday, 12'th Nov 2024
WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported f
Synlogic Reports Second Quarter 2024 Financial Results
07:00am, Thursday, 08'th Aug 2024
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported f
The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits
03:29pm, Thursday, 23'rd May 2024
“Sell in May and go away” is a common adage in investing. It's based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines.
Synlogic Reports First Quarter 2024 Financial Results
07:00am, Tuesday, 14'th May 2024
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported fin
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
09:10am, Tuesday, 19'th Mar 2024
Synlogic, Inc. (SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago.
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
07:00am, Tuesday, 19'th Mar 2024
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported f
Synlogic Adopts Limited Duration Stockholders Rights Plan
12:15pm, Tuesday, 20'th Feb 2024
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strateg
Why Is Synlogic (SYBX) Stock Down 55% Today?
08:42am, Friday, 09'th Feb 2024
Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release fro
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
04:15pm, Thursday, 08'th Feb 2024
Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to p
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study
Synlogic Provides Corporate Update and Outlook for 2024
07:00am, Thursday, 04'th Jan 2024
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age -
Synlogic Announces Contract with the Air Force Research Lab
07:00am, Wednesday, 27'th Dec 2023
- Selection of Synlogic reflects Company's leadership in process development and manufacturing of therapeutics based on synthetic biology - - Selection of Synlogic reflects Company's leadership in pro
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
07:00am, Thursday, 07'th Dec 2023
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation -
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07:00am, Thursday, 09'th Nov 2023
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 -
Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:18am, Thursday, 02'nd Nov 2023
Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
